Application of glycolysis key enzyme in anti-tumor therapeutic drug

A therapeutic drug and key enzyme technology, applied in the direction of antineoplastic drugs, drug combinations, medical preparations containing active ingredients, etc., can solve problems such as large side effects, damage to normal cells, and patient pain

Inactive Publication Date: 2022-03-01
AFFILIATED HOSPITAL OF GUILIN MEDICAL UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] However, the existing technology has the following disadvantages: although traditional cancer treatment methods can inhibit malignant tumors to a certain extent, they have large side effects and damage to normal cells. Disadvantages such as low curative effect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of glycolysis key enzyme in anti-tumor therapeutic drug
  • Application of glycolysis key enzyme in anti-tumor therapeutic drug
  • Application of glycolysis key enzyme in anti-tumor therapeutic drug

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0013] This embodiment provides an application of a key enzyme of glycolysis in an anti-tumor drug, specifically, one of the key enzymes of glycolysis is the GAPDH1 protein in Drosophila.

[0014] Ras is one of the earliest discovered proto-oncogenes. It is a small molecular weight G protein located on the membrane, which becomes activated or inactivated as it binds to GTP or GDP, thereby regulating downstream Raf, P13K, and other signaling pathways. It is mutated in about 30% of human tumors. Ras V12 It is a constitutive activating mutation in which the glycine at position 12 of the Ras protein is mutated to valine. In subcultured cells or mice, overexpression of Ras V12 It is an important means to study tumorigenesis and metastasis. In Drosophila, overexpression of Ras V12 The clones will proliferate rapidly and form tumors, so the overexpression of Ras is selected V12 Drosophila tumor models for screening anticancer drugs.

[0015] In order to verify the effect, foll...

Embodiment 2

[0026] Similar to Example 1, the difference is that in this example, the key enzyme of glycolysis refers to the GAPDH2 protein in Drosophila.

[0027] In the same way as in Example 1, the GAPDH2 protein was introduced into Ras exogenously V12 ; In the scrib- / - tumor model, stereoscopic fluorescence microscope observation revealed that the size of tumors introduced with GAPDH2 protein was significantly reduced (eg image 3 ), the fluorescence intensity decreased significantly (such as Figure 4 ), indicating that GAPDH2 can also significantly inhibit tumor growth.

Embodiment 3

[0029] Based on the above-mentioned embodiments, this embodiment provides an anti-tumor therapeutic drug, which includes the key enzyme of glycolysis involved in any one of the above-mentioned embodiments.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides an application of a glycolysis key enzyme in an anti-tumor therapeutic drug. The glycolysis key enzyme GAPDH refers to GAPDH1 or GAPDH2 protein in fruit flies in the invention. The GAPDH1 and GAPDH2 proteins can be used for efficiently and specifically treating cancers caused by human Ras gene mutation. According to the characteristic that the expression quantity of GAPDH in tumors is remarkably reduced, the aim of remarkably inhibiting the tumors is achieved by exogenously increasing the protein quantity of fruit fly GAPDH1 and GAPDH2, and the application is high in pertinence and remarkable in tumor inhibiting effect.

Description

technical field [0001] The invention relates to the application of glycolytic key enzymes in antitumor therapeutic drugs. Background technique [0002] As one of the largest public health problems in the world, malignant tumors have greatly endangered human health. In recent years, due to the acceleration of industrialization, urbanization, population aging and environmental pollution, the situation of malignant tumors in my country has become more and more serious. The overall incidence rate is on the rise, with an average annual incidence rate of 3%-5%. According to the number of malignant tumors in 2014, the top ten malignant tumors are lung cancer, gastric cancer, colorectal cancer, liver cancer, breast cancer, esophageal cancer, thyroid cancer, cervical cancer, brain cancer, and pancreatic cancer. Carcinoma is the most common cancer in men and women respectively. Traditional cancer treatment is mainly based on surgical resection, radiotherapy, and chemotherapy. Surgi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/44A61P35/00
CPCA61K38/443C12Y101/01008A61P35/00
Inventor 李清华韦载娲文雪怡王文晶
Owner AFFILIATED HOSPITAL OF GUILIN MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products